Business
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
OSAKA, Japan & CAMBRIDGE, Mass., November 03, 2025--Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and risk profile of QDENGA and that the two-dose regimen provides sustained protection against dengue. T
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":266,"url":"https://media.zenfs.com/en/business-wire.com/ab10eb0d611798e4ff517e42282c3b5b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OnHqMzPOWfvLzfd1UQ7nug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ab10eb0d611798e4ff517e42282c3b5b","width":480,"height":266}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination Schedule","length":86,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":86,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"QDENGA is the Longest-Studied Dengue Vaccine and the Only Approved for Use Regardless of Prior Disease Exposure","length":111,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":111,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Takeda is Expanding Global Access to QDENGA in Partnership with National Immunization Programs, Private Payors and Public Health Coalitions, with 18.6 Million Doses Distributed in 11 Endemic Countries","length":200,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":200,"olType":false},{"type":"text","content":"OSAKA, Japan & CAMBRIDGE, Mass., November 03, 2025--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and risk profile of QDENGA and that the two-dose regimen provides sustained protection against dengue. This is consistent with its approved indications in multiple countries worldwide, which could simplify vaccination schedules and increase adherence.","length":668,"tagName":"p"},{"type":"text","content":""We are seeing an unprecedented surge in dengue, with over 14 million cases reported across more than 100 countries in 2024 alone, largely driven by the impacts of climate change and inadequate urbanization. Brazil, consistently among t...